Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience.

Median RFS was numerically improved with adjuvant chemotherapy, although this did not reach statistical significance (162.9 months with adjuvant chemotherapy vs. 109.2 months without adjuvant chemotherapy (hazard ratio [HR]=0.57; 95% CI=0.25, 1.32; log-rank p=0.19) ( Fig. 1 ). 3.

also in 111,027 other papers